Photo

Photo detail

Stories this photo appears in:

Edwards Shares Fall on Sapien Sales

Shares of Edwards Lifesciences Corp. in Irvine fell 15% to about $96.50 a share and a $20 billion market cap on a lower-than-expected increase in its most recent quarter on international sales of its main product, the Sapien heart valves.

Tease photo

Edwards Beats on Q2

Irvine-based Edwards Lifesciences Corp. surpassed analysts' expectations on second-quarter revenue and profit and hiked its 2016 forecast in a report issued after markets closed today.

Tease photo

Edwards Beats Estimates

Irvine-based Edwards Lifesciences Corp. today reported better-than-expected first-quarter profit and revenue.

Tease photo

Edwards Surges on Valve Trial

Irvine-based Edwards Lifesciences Corp.’s shares shot up today after it reported positive results on a pair of less-invasive replacement heart valve clinical trials.

Tease photo

Edwards Beats on Q4; Ups Guidance

Irvine-based Edwards Lifesciences Corp. beat analyst expectations on quarterly revenue and profit and boosted full-year expectations in a report issued after markets closed Tuesday.

Tease photo

Edwards Beats, Shares Rise

Irvine-based Edwards Lifesciences Corp. reported financial results today that exceeded expectations and sent its shares up in after-hours trading.

Tease photo

Edwards Works With CareFusion

Irvine-based cardiovascular device maker Edwards Lifesciences Corp. said today that it signed a deal with San Diego-based CareFusion, a BD company, to enable a pair of their respective devices to work together.

Tease photo

FDA Clears Additional Use for Edwards Sapien XT

Irvine-based Edwards Lifesciences Corp. said today that the Food and Drug Administration approved its Edwards Sapien XT replacement heart valve for aortic valve-in-valve procedures.

Tease photo

Edwards Beats on Profit, EPS Down in Q2

Irvine-based Edwards Lifesciences Corp. reported financial results today that exceeded analysts’ forecasts in some areas though earnings per share declined.

Tease photo

Edwards Suspends Valve Study

Irvine-based Edwards Lifesciences Corp. said today that it is voluntarily halting enrollment in an early clinical trial for an experimental, less-invasive mitral heart valve.

Tease photo

Edwards Posts Profit

Irvine-based Edwards Lifesciences Corp. reported a profit of $123.4 million, more than double the total for the same period a year ago.

Tease photo